Insider Trading Alert - LCI, EL And CI Traded By Insiders

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Yesterday, Aug. 20, 2014, 93 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $712.40 to $14,201,355.08.

Highlighted Stocks Traded by Insiders:

Lannett (LCI) - FREE Research Report

Bedrosian Arthur P, who is President and CEO at Lannett, sold 5,000 shares at $41.30 on Aug. 20, 2014. Following this transaction, the President and CEO owned 643,817 shares meaning that the stake was reduced by 0.77% with the 5,000-share transaction.

Farber David, who is 10% Owner at Lannett, sold 5,000 shares at $41.30 on Aug. 20, 2014. Following this transaction, the 10% Owner owned 75,870 shares meaning that the stake was reduced by 6.18% with the 5,000-share transaction.

The shares most recently traded at $35.39, down $5.91, or 16.7% since the insider transaction. Historical insider transactions for Lannett go as follows:

  • 4-Week # shares bought: 500
  • 4-Week # shares sold: 10,000
  • 12-Week # shares bought: 500
  • 12-Week # shares sold: 23,500
  • 24-Week # shares bought: 500
  • 24-Week # shares sold: 33,500

The average volume for Lannett has been 687,500 shares per day over the past 30 days. Lannett has a market cap of $1.3 billion and is part of the health care sector and drugs industry. Shares are up 10.63% year-to-date as of the close of trading on Wednesday.

Lannett Company, Inc. develops, manufactures, packages, markets, and distributes generic versions of branded pharmaceutical products in the United States. It offers solid oral, extended release, topical, and oral solution finished dosage forms of drugs that address a range of therapeutic areas. The company has a P/E ratio of 33.4. Currently, there are 4 analysts who rate Lannett a buy, no analysts rate it a sell, and 1 rates it a hold.

Exclusive Offer: Get the latest Stock Analysis on LCI - FREE

TheStreet Quant Ratings rates Lannett as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, solid stock price performance, impressive record of earnings per share growth and compelling growth in net income. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook. Get the full Lannett Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

If you liked this article you might like

Lannett Scores FDA OK for Nexium Generic-Biotech Movers

Teva, Mylan Seen to Stay on M&A Sidelines

Teva's Massive Debt Load Just Became an Even Bigger Issue

Teva Shares Are Getting Obliterated Again After Vicious Investment Bank Downgrades

Teva Shares Are Taking a Beating and Dragging Down the Generic Drugmakers